These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9295927)

  • 1. [Calcium antagonists and development of the atheromatous plaque].
    Weber S
    Arch Mal Coeur Vaiss; 1997 May; 90 Spec No 2():51-3. PubMed ID: 9295927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part II. Clinical experience with preventive effects of calcium channel blockers in atheromatous coronary artery disease.
    Just H; Frey M
    Basic Res Cardiol; 1994; 89 Suppl 1():177-84. PubMed ID: 7945172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of calcium antagonists on atherosclerosis progression and intima media thickness].
    Zannad F
    Drugs; 2000; 59 Spec No 2():39-46. PubMed ID: 11002857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atheroma and calcium antagonists].
    Lechat P; Hadjiisky P
    Therapie; 1993; 48 Spec No():665-70. PubMed ID: 8091352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modification of coronary arteriosclerosis in man by calcium antagonists?].
    Schneider W; Roebruck P; Cieslinski G; Noack H; Kober G; Alle M; Kaltenbach M
    Z Kardiol; 1991; 80 Suppl 9():63-71. PubMed ID: 1796651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiatherogenic properties of calcium antagonists.
    Bond MG; Purvis C; Mercuri M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S87-92; discussion S92-3. PubMed ID: 1726013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of various calcium antagonists against experimental arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Fleckenstein A
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S13-8. PubMed ID: 1293304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers and the prevention of atherosclerosis.
    Gotto AM
    Am J Hypertens; 1990 Dec; 3(12 Pt 2):342S-346S. PubMed ID: 2078321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of calcium antagonists and atherosclerosis.
    Keogh AM; Schroeder JS
    J Cardiovasc Pharmacol; 1990; 16 Suppl 6():S28-35. PubMed ID: 1707112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of anti-atheromatous properties of calcium channel inhibitors].
    Drici MD; Coccoz F; Morand P; Lapalus P
    Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():161-5. PubMed ID: 1285697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part I. Preventive effects of calcium antagonists in animal experiments.
    Frey M; Just H
    Basic Res Cardiol; 1994; 89 Suppl 1():161-76. PubMed ID: 7945170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
    Jost S; Rafflenbeul W; Deckers J; Wiese B; Hecker H; Nikutta P; Lippolt P; Lichtlen P
    Eur J Epidemiol; 1992 May; 8 Suppl 1():107-19. PubMed ID: 1505647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium antagonists and atherosclerosis.
    Betz E; Weiss HD; Heinle H; Fotev Z
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S71-5. PubMed ID: 1725009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of the usefulness of selected biochemical parameters for assessing the advanced atheromatous changes in human coronary arteries].
    Bukowska H
    Ann Acad Med Stetin; 1998; 44():29-43. PubMed ID: 9857530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current data on atheromatous plaques and their evolution].
    Bauters C; Van Belle E; McFadden E; Bertrand M
    Arch Mal Coeur Vaiss; 1998 Oct; 91 Spec No 5():9-12. PubMed ID: 9833074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis.
    Bangalore S; Parkar S; Messerli FH
    Am J Med; 2009 Apr; 122(4):356-65. PubMed ID: 19332231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study.
    Banasiak W; Wilkins A; Pociupany R; Ponikowski P
    Kardiol Pol; 2008 Jun; 66(6):642-9; discussion 650. PubMed ID: 18626833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Physiopathology of acute coronary syndromes].
    Quilici J; Gallo R
    Ann Cardiol Angeiol (Paris); 1999 Nov; 48(9-10):611-23. PubMed ID: 12555467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.